

EQA round: RF1/25 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 14.3.2025

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
Set 1															
(277) anti-CCP IgG	[kU/L]				14										0
Sample A1		2,12	2,1	100	14										0
Other					14	1									0
							4x 1, 1x 29, 2x 60, 1x 66, 2x 135, 1x 140, 1x 148, 1x 179, 1x 999								0
Sample B1		297	130	45	14										0
Other					14	4									0
							4x 1, 1x 29, 2x 60, 1x 66, 2x 135, 1x 140, 1x 148, 1x 179, 1x 999								0
(282) anti-MCV IgG	[kU/L]				5										0
Sample A1		6,36	2,2	34	5										0
Other					5	0									0
							1x 34, 4x 135								0
Sample B1		896	150	17	5										0
Other					5	0									0
							1x 34, 4x 135								0
(231) Rheumat. fac. (scr)	[kU/L]				19										0
Sample A1		6,45	2,5	39	19										0
(58) Beckman Coulter (AU)		6,5	0,89	14	5	0	CVPG	6,63	0,95	33%	4,44	8,82			0
(60) Roche		6,45	0,82	13	6	2	CVPG	8,7	0,65	33%	5,82	11,6			0
Other					8	0									0
							3x 1, 1x 75, 1x 148, 1x 162, 1x 178, 1x 179								0
Sample B1		366	140	39	19										0
(58) Beckman Coulter (AU)		457	11	2,3	5	0	CVPG	453	16	33%	303	603			0
(60) Roche		310	200	64	6	2	CVPG	446	6,7	33%	298	594			0
Other					8	0									0
							3x 1, 1x 75, 1x 148, 1x 162, 1x 178, 1x 179								0
(233) Rheumat. factor IgG	[kU/L]				1										0
Sample A1		7,42			1										0
Other					1	0									0
							1x 58								0
Sample B1		466			1										0
Other					1	0									0
							1x 58								0
Set 2															
(237) anti-streptolysin O (ASLO)	[kU/L]				21										19
Sample A2		163	13	7,7	21										19
(58) Beckman Coulter (AU)		169	5,2	3,1	9	0	CVPG	165	3,4	20%	132	198			9
(60) Roche		168	16	9,5	6	0	CVPG	165	3,3	20%	132	198			6
Other					6	0									4
							3x 1, 1x 162, 2x 178								4
Sample B2		327	20	6,1	21										19
(58) Beckman Coulter (AU)		326	5,9	1,8	9	0	CVPG	326	4	20%	260	392			9
(60) Roche		346	35	10	6	0	CVPG	348	6,6	20%	278	418			6
Other					6	0									4
							3x 1, 1x 162, 2x 178								4